Reference
Kim JT, et al. Patient with stage iv nsclc and cns metastasis with egfr exon 18-25 kinase domain duplication with response to osimertinib as a first-line therapy. JCO Precision Oncology 5: 88-92, Jan 2021. Available from: URL: http://doi.org/10.1200/PO.20.00296
Rights and permissions
About this article
Cite this article
Afatinib/osimertinib. Reactions Weekly 1902, 24 (2022). https://doi.org/10.1007/s40278-022-13168-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-13168-9